Subscribe to our newsletter to get free stock market tips and investment advice! RSS Feed

Welcome, Guest. Please login or register.
Did you miss your activation email? Tagged Keywords

AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes

Stock Market Forums > Qwoter Announcements > Qwoter Press Wire > AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes

Pages: [1]

	Author	Topic: AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes (Read 478 times)
0 Members and 1 Guest are viewing this topic.

The Web Team

Hero Member

Karma: 14
Posts: 8755

AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes

« on: July 31, 2008, 07:12:07 AM »

AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes

<p>Company to Host Conference Call and Webcast on July 31, 2008 at 9 a.m. EDT</p>

http://www.marketwire.com/mw/release.do?id=884633&sourceType=3


	Logged

The Web Team
Qwoter.com

Stock Market Forums

AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes

« on: July 31, 2008, 07:12:07 AM »


	Logged

Pages: [1]

Related Topics
	Subject	Views	Started by
	AtheroGenics to Report Third Quarter 2007 Financial Results on October 25, 2007 Qwoter Press Wire	573	The Web Team
	AtheroGenics to Report Fourth Quarter and Year-End 2007 Financial Results on February 14, 2008 Qwoter Press Wire	428	The Web Team
	Transdel Pharmaceuticals Submits to the FDA the Phase 3 Clinical Study of Ketotransdel(TM) for the Treatment of Acute Pain Qwoter Press Wire	491	The Web Team
	Prana Announces Success in Phase IIa Clinical Trial Qwoter Press Wire	501	The Web Team
	AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes Qwoter Press Wire	521	The Web Team
	Pipex Pharmaceuticals to Provide Clinical Update and Report First Quarter 2008 Results on Thursday, May 15 Qwoter Press Wire	599	The Web Team
	Pipex Pharmaceuticals to Host Conference Call at 10:15am ET Wednesday July 9th to Discuss Phase II Clinical Trial Results in Dry Age-Related Macular Degeneration (AMD) With Oral Z-Monocys Qwoter Press Wire	538	The Web Team
	Theravance Announces Clinical Results in the LAMA Respiratory Program for the Treatment of COPD Qwoter Press Wire	530	The Web Team
	FX Energy Reports Log Results in the Kromolice-1 Well Qwoter Press Wire	432	The Web Team
	Adeona Pharmaceuticals to Provide Clinical Update and Report Third Quarter 2008 Results Qwoter Press Wire	865	The Web Team

Jump to: